UVA Center for Leading Edge Addiction Research
Charlottesville, Virginia, 22903, United States
NCT Number: NCT03969238
The investigator propose to develop an opioid telephone helpline, where trained counselors and educators provide referral, educational and targeted interventions and support to individuals interested in addressing their addiction or needing help with managing their pain. The proposed application builds on "tobacco quit line" efforts, a nationally-adopted telephone-based service, providing education materials, access to cessation medication and counseling against tobacco use. Similar to tobacco quit line; the proposed telephone based services will remove barriers to treatment as they help individuals at the exact time of need. The helpline will also educate individuals with new onset pain about pain expectations, relaxation techniques, use of pharmacology and psychotherapy for treatment in addition to providing support for coping and reducing dependency on prescription opioids. It will be a low cost, easily accessible and utilizable technology to augment the clinical outcome of medication assisted treatment of opioid use disorder and pain management.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Charlottesville, Virginia, 22903, United States
The proposed specific aims are to:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Participant Criteria:
Provider Criteria:
Exclusion criteria
Participant Criteria:
Provider Criteria:
Providers outside the designated regions.
This helpline will aim to provide patients with new diagnosis of pain who are prescribed opioids, access to education, support and free behavioral technique to help manage their pain such as mindfulness exercises. For those with opioid use disorder, the helpline will offer support in the form of education about the disorder, opioid withdrawal symptoms, risks of overdoses, and a variety of services such as help reach appropriate care with MAT licensed providers, information on FDA-approved MAT and naloxone, and, in some cases, behavioral intervention to keep patients engaged in treatment. The opioid helpline will provide a central resource for direct services and a portal for community services. It will also serve as a referral resource for health-care professionals.
Time frame: up to a year
Primary outcomes measure the rating of the Helpline by the patients. They will be sent surveys that will ask the patients to rate the services they receive on a scale of 1 to 10, with 1 meaning they are very dissatisfied and 10 meaning they are very satisfied.
Time frame: up to a year
Primary outcomes measure the rating of the Helpline by the providers. They will be sent surveys that will ask the providers to rate the services they receive on a scale of 1 to 10, with 1 meaning they are very dissatisfied and 10 meaning they are very satisfied.
Time frame: up to a year
Total number of contacts to the Helpline compared to the number that prescreened and the number consented.
Time frame: up to a year
The investigator will measure the number of participants who continued to access the services of Helpline up to a year.
Time frame: up to a year
By using this survey, the investigator will determine the participant's ability to handle the situation that prompted the participant to call the Helpline originally.
Time frame: up to a year
This will be use to collect demographic information for individuals who self-identify as needing help or resources from the Helpline.
Time frame: up to a year
Assess which referrals were followed up on by the participants.
University of Virginia
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02359006
Agnosia, Chemically-Induced Disorders
West Haven, Connecticut, United States
View Trial DetailsNCT04325659
Chemically-Induced Disorders, Mental Disorders
Baltimore, Maryland, United States
View Trial DetailsNCT04454645
Chemically-Induced Disorders, Infant Development
Newark, Delaware, United States
View Trial DetailsNCT03089983
Acquired Immunodeficiency Syndrome, Actinomycetales Infections
Kajang, Selangor, Malaysia
View Trial Details